Skip to main content

Table 2 Model results

From: A comparative cost-effectiveness analysis of mechanical and pharmacological VTE prophylaxis after lower limb arthroplasty in Australia

  ICER vs IPC, AUD per QALY gained CE QALY simulations vs IPC, % ICER vs IPC, AUD per VTE avoided CE VTE simulations vs IPC, %
LMWH Dominated 1.2 Dominated 0.2
Apixaban 12,656 76.4 3022 46.4
Dabigatran 51,224 55.2 73,824 21.4
Rivaroxaban 55,714 30.8 10,947 10
IPC + LMWH (7 days + 23 days) Dominated 1.8 Dominated 3.2
IPC + apixaban (7 days + 23  days) 14,000 87.8 4960 36.6
  1. Outcomes and costs of the assessed treatment modalities compared to IPC. ICER vs IPC, AUD per QALY gained: incremental costs to gain one additional QALY; CE QALY simulations vs. IPC: percent of simulations where the comparator was considered more cost-effective than IPC regarding quality of life; ICER vs IPC, AUD per VTE avoided: incremental costs to avoid one additional VTE event; CE VTE simulations vs IPC: percentage of simulations where the comparator was considered more cost-effective than IPC regarding VTE prevention
  2. AUD Australian dollars, CE cost-effective, Dominated more expensive and fewer QALYs accumulated compared to IPC alone, ICER incremental cost-effectiveness ratio, IPC intermittent pneumatic compression, LMWH low-molecular-weight heparin, QALY quality-adjusted life year, VTE venous thromboembolism